NCT06001788 2025-12-03Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1 Recruiting171 enrolled
NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT04104776 2025-05-15A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNovartisPhase 1/2 Recruiting275 enrolled
NCT04601584 2024-03-06GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALLAO GENERIUMPhase 1/2 Recruiting36 enrolled